VC-backed Metacrine goes public

San Diego-based Metacrine, a developer of therapies for patients with liver, gastrointestinal and metabolic diseases, has raised about $85 million for its IPO after pricing its 6.54 million shares at $13 per share.

To read this article, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to read this article and more for free.

Share this